What Happened?
Philadelphia, PA-based Aro Biotherapeutics Appointed Susan Dillon as President and Chief Executive Officer
About the Company
Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
About the Person
Susan Dillon is President and Chief Executive Officer at Aro Biotherapeutics. Previously, Susan held various senior HR leadership roles in the industry.
Info Source
News
Short Profile